



Response under 37 CFR § 1.116  
--EXPEDITED PROCEDURE--  
Examining Group 1644

## PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Express Mail No: EL728730437US  
Date of Deposit: October 22, 2001

#23/C  
gns  
12.19.01  
(K.E.)  
RECEIVED  
DEC 11 2001  
TECH CENTER 1600/2900

Application of: Faustman et al.

Serial No.: 09/031,629

Filed: February 27, 1998

Entitled: METHODS FOR DIAGNOSING AND  
TREATING AUTOIMMUNE DISEASE

Atty. Docket No.: 17633/1030 {formerly 11275/8407}

--EXPEDITED PROCEDURE--

Examiner: P. Nolan

Art Unit: 1644

**Box: AF**

Commissioner for Patents  
Washington, D.C. 20231

### AMENDMENT AND RESPONSE TO OFFICE ACTION

Sir:

This Amendment is filed in response to the Office Action, dated July 5, 2001, in the above-identified application.

Kindly consider the following amendments and remarks.

In the Claims:

Kindly replace claims 65, 70 and 71 with the following:

65. A method of screening for autoimmune disease associated with a reduction in NF $\kappa$ B activity in a mammal deemed to be at risk for an autoimmune disease, comprising:

- a) providing a biological sample from a mammal; and
- b) detecting activity of proteasomes in said sample by measuring the level of proteolytic products derived from the proteolytic processing of NF $\kappa$ B by said proteasomes generated by said proteasomes, wherein a reduction in the level of said proteolytic products from a basal state is